Breaking News
Za Pharmacy
Drugs, Supplies and Delivery
Yasmin (Ethinylestradiol/Drospirenone)
Yasmin is a combined oral contraceptive (COC) pill containing ethinylestradiol (a synthetic estrogen) and drospirenone (a synthetic progestin). Approved for contraception and other therapeutic uses, it is widely prescribed due to its unique pharmacological profile. This article explores its mechanism of action, uses, dosage, side effects, precautions, and drug interactions, referencing key pharmacological texts.
Yasmin’s contraceptive effect arises from synergistic actions of its components:
- Ovulation Suppression: Ethinylestradiol suppresses follicle-stimulating hormone (FSH), inhibiting follicular development, while drospirenone blocks the luteinizing hormone (LH) surge, preventing ovulation (Lippincott Textbook of Pharmacology).
- Cervical Mucus Thickening: Drospirenone alters cervical mucus, impeding sperm penetration.
- Endometrial Changes: Progestin thins the endometrial lining, reducing implantation potential (Lange Basic & Clinical Pharmacology).
Drospirenone, a spironolactone analogue, also exhibits anti-androgenic (reducing acne) and anti-mineralocorticoid effects (mitigating fluid retention), broadening its therapeutic applications.
- Contraception: Primary use, with >99% efficacy when taken correctly (BNF).
- Acne Management: Approved for moderate acne in women seeking contraception, leveraging drospirenone’s anti-androgenic activity.
- Premenstrual Dysphoric Disorder (PMDD): Alleviates emotional and physical symptoms via hormonal stabilization (Lippincott).
- Standard Regimen: One tablet (0.03 mg ethinylestradiol + 3 mg drospirenone) daily for 21 days, followed by a 7-day placebo/break. Restart on day 8, even if bleeding occurs (BNF).
- Initiation: Start on menstrual cycle day 1 or the first Sunday after onset. Backup contraception is advised for the first 7 days.
- Missed Dose: Follow BNF guidelines: If <24 hours late, take immediately; if >24 hours, additional contraception is required.
- Common: Nausea, headache, breast tenderness, breakthrough bleeding.
- Serious:
- Venous Thromboembolism (VTE): Risk elevated compared to levonorgestrel-containing pills (BNF).
- Hyperkalemia: Due to drospirenone’s mineralocorticoid antagonism; monitor in high-risk patients (Lange).
- Hepatic Issues: Rare hepatocellular carcinoma or benign adenomas.
- Absolute Contraindications: History of VTE, cardiovascular disease, migraine with aura, estrogen-sensitive cancers, severe liver disease, or undiagnosed vaginal bleeding (BNF).
- Relative Precautions: Hypertension, diabetes, obesity, or renal impairment (drospirenone is contraindicated in adrenal insufficiency or severe renal dysfunction).
- Monitoring: Check potassium levels in patients on potassium-sparing drugs or with renal impairment (Lippincott).
- Efficacy Reduction: Enzyme inducers (e.g., rifampicin, carbamazepine, St. John’s Wort) accelerate metabolism, risking contraceptive failure (BNF).
- Hyperkalemia Risk: Concomitant use with ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics necessitates monitoring (Lange).
- Hormonal Interactions: Broad-spectrum antibiotics (e.g., rifampicin) may reduce efficacy; consider backup methods.
- Active Ingredients: Ethinylestradiol (alternatively spelled ethinyl estradiol) and drospirenone.
- Brands: Marketed as Yasmin; generics may be labeled as ethinylestradiol/drospirenone.
